Amarantus Biosci Inc (AMBS) 0.1935 $AMBS
Sidney Rice and Ben Utecht Talk to NFL Network's Andrea Kremer and ESPN's Andrew Brandt at Upcoming #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Mon Jul 28, 2:16PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to provide an update surrounding the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Amarantus Appoints Donald D. Huffman to Board of Directors
GlobeNewswire - Mon Jul 28, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced the appointment of Donald D. Huffman to the Company's Board of Directors, where he will chair the newly-formed audit committee. Mr. Huffman brings over 20 years of biopharmaceutical industry experience in various financial and audit roles, with specific expertise in mergers and acquisitions.
Amarantus and BSI Announce Dr. Thomas Arendt as Presenter at 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations
GlobeNewswire - Wed Jul 23, 10:34AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced a presentation by Dr. Thomas Arendt, Professor at University of Leipzig, at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY. Dr. Arendt will summarize his scientific hypotheses regarding the evolutional context of Alzheimer's disease, and an emerging therapeutic target in a 30 minute presentation in the afternoon session.
Amarantus and BSI Proudly Announce BIO CEO & President Jim Greenwood as Panelist for 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations
GlobeNewswire - Tue Jul 22, 2:47PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are proud to announce the Honorable Jim Greenwood, President & CEO of the Biotechnology Industry Organization (BIO), as a panelist for the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014, at the United Nations in New York City, NY.
Amarantus Discusses New Independent Peer-Reviewed Research Papers on MANF
GlobeNewswire - Fri Jul 18, 6:49AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has updated its MANF publications list with 8 previously undisclosed independent peer-reviewed research papers. The scientific articles include several Chinese publications as well as new publications that have been released since the beginning of 2014.
Amarantus BioScience Holdings, Inc. - "Understanding Data Presented at AAIC and Why Amarantus is Well Positioned Heading into #C4CT"
ACCESSWIRE - Thu Jul 17, 1:00PM CDT
New York, NY / July 17, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus and BSI Announce Continued Support of One Mind at the 3rd #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Thu Jul 17, 7:17AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, andAmarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to announce their continued support of One Mind at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Amarantus Announces Positive Clinical Performance and 7-Year Longitudinal Data Poster Presentations for LymPro Test (R) at AAIC 2014
GlobeNewswire - Tue Jul 15, 10:34AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive clinical performance data for Version 2 of the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. The LymPro Test clinical data package assessed was produced in 2008 at Provista Life Sciences. The 7-year longitudinal patient record clinical progression assessment data was conducted by Dr. Marwan Sabbagh at the Banner Sun Health Research institute who originally enrolled the 44 patients involved in the Provista clinical trial, and analyzed by Dr. Louis Kirby, the Company's Chief Medical Officer. LymPro differentially diagnosed Alzheimer's disease versus age-matched other dementias and cognitively intact controls in statistically significant manner. The poster presentations are available online at http://ir.stockpr.com/amarantus/scientific-publications.
Amarantus Announces Positive Analytical Performance Data Poster Presentation for LymPro Test (R) at AAIC 2014
GlobeNewswire - Mon Jul 14, 7:58AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive analytical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. The analytical data package, produced at the Company's contract laboratory BD Biosciences, provides the basis for reproducible clinical performance assessment of LymPro Test(R). The Company has performance univariate and multivariate analytical data analyses in an Alzheimer's population vs. a non-Alzheimer's population (cognitively intact, Parkinson's dementia and vascular dementia) to assess clinical performance. The Company will present pilot clinical performance data, and an up-to 6 year longitudinal assessment of the patients' clinical diagnosis change over time, in two complementary poster presentations on Tuesday July 15, 2014 at 11:45am local at AAIC 2014 in Copenhagen, Denmark (Poster position 117 and 118).
Amarantus BioScience Holdings "AAIC 2014: Understanding the Data Being Presented - LymPro Test(r) Version 2"
ACCESSWIRE - Wed Jul 09, 3:46PM CDT
New York, NY / ACCESSWIRE / July 9, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus' CEO to Host Twitter Chat on Thursday, July 10, 2014 at 4pm EDT
GlobeNewswire - Mon Jul 07, 3:25PM CDT
Amarantus BioScience Holdings, Inc. (OTCBB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will host and participate in a Twitter chat on Thursday, July 10, 2014 from 4-4:30pm EDT via his Twitter handle @G_Commish.
Amarantus Announces Three Data Presentations Related to the Company's LymPro Diagnostic Test at the Alzheimer's Association International Conference (AAIC)
GlobeNewswire - Mon Jul 07, 7:30AM CDT
Amarantus BioScience Holdings, (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that analytical performance, clinical performance and 6-year longitudinal data related to the Company's LymPro Test(R) will be presented at the Alzheimer's Association International Conference (AAIC), held at the Bella Center in Copenhagen, Denmark, July 12-17, 2014.
Amarantus Announces Positive Interim Toxicology Data for MANF in Retinitis Pigmentosa
GlobeNewswire - Wed Jul 02, 8:58AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive interim toxicology data for MANF in an ocular safety animal model, relevant to MANF development in Retinitis Pigmentosa. The data produced at a leading ophthalmology contract research laboratory using slit-lamp observations in rabbits demonstrated that an intravitreal injection with MANF was safe and well tolerated in the eye.
Active Trading Briefing For Innovative Advancers with Developing Operations - Company Enters Strategic Partnership With Renown Global Investment Advisory Firm
PR Newswire - Tue Jul 01, 7:45AM CDT
Operations and corporate developments lead to growth trends for advancing companies across various sectors: DirectView Holdings, Inc (OTC: DIRV), Amarantus Bioscience Holdings, Inc. (OTC: AMBS), The ADT Corporation (NYSE: ADT), Tyco International Ltd. (NYSE: TYC) and GoPro Inc. (NASDAQ: GPRO)
Amarantus Independently Confirms Published Chinese Positive MANF Tau Phosphorylation Data for Alzheimer's Disease
GlobeNewswire - Tue Jul 01, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced it has independently confirmed MANF's activity in mitigating tau hyperphosphorylation in pre-clinical models of Alzheimer's disease. The studies commissioned by Amarantus independently confirm data published in 2012 in the Chinese Pharmacological Bulletin entitled "MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells" in which the authors demonstrated that MANF had a pronounced effect in reducing Tau hyperphosphorylation, reducing cell death, and improving overall cellular health in in vitro models of Alzheimer's disease.
Amarantus BioScience Holdings, Inc. - "MANF Continues to Deliver Heading into 2H-14"
ACCESSWIRE - Mon Jun 30, 2:01PM CDT
New York, NY / June 30, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus and Brewer Sports Announce #C4CT Summit Morning Keynote Presentation by Congressman Chaka Fattah
GlobeNewswire - Wed Jun 25, 5:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International (BSI), today announced that Congressman Chaka Fattah will be delivering the morning keynote address at the #C4CT Concussion Awareness Summit focused on Traumatic Brain Injury-induced Alzheimer's disease at the United Nations on July 31, 2014. Congressman Fattah will address the Summit regarding policy initiatives currently underway to improve funding for Brain research.
Amarantus Bioscience Holdings, Inc. - "Marching Towards a Revolutionary Therapy for Blindness and Diabetes in Wolfram Syndrome"
ACCESSWIRE - Tue Jun 24, 10:01AM CDT
New York, NY / June 24, 2014 / Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) today published a guest blog post on The Chairman's Blog, written by Dr. Fumihiko Urano, a researcher at the Washington University School of Medicine. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus to Present at the 2014 BIO International Convention
GlobeNewswire - Mon Jun 23, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be presenting at the 2014 BIO International Convention on Thursday, June 26 at 11:45 AM PDT. The presentation will take place in the Mission Beach Room. Hosted by the Biotechnology Industry Organization (BIO), the conference will take place on June 23-26, 2014 at the San Diego Convention Center in San Diego, California.
Amarantus partners with Washington University School of MedicineJack to evaluate the efficacy of MANF to treat Wolfram disease
M2 - Mon Jun 23, 4:35AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) said on Friday that it plans to evaluate the efficacy of MANF to treat Wolfram-Syndrome-induced blindness in animals in a research partnership with the Washington University School of Medicine in St. Louis.
Sidney Rice and Ben Utecht Talk to NFL Network's Andrea Kremer and ESPN's Andrew Brandt at Upcoming #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Mon Jul 28, 2:16PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to provide an update surrounding the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Amarantus Appoints Donald D. Huffman to Board of Directors
GlobeNewswire - Mon Jul 28, 7:41AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced the appointment of Donald D. Huffman to the Company's Board of Directors, where he will chair the newly-formed audit committee. Mr. Huffman brings over 20 years of biopharmaceutical industry experience in various financial and audit roles, with specific expertise in mergers and acquisitions.
Amarantus and BSI Announce Dr. Thomas Arendt as Presenter at 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations
GlobeNewswire - Wed Jul 23, 10:34AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced a presentation by Dr. Thomas Arendt, Professor at University of Leipzig, at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY. Dr. Arendt will summarize his scientific hypotheses regarding the evolutional context of Alzheimer's disease, and an emerging therapeutic target in a 30 minute presentation in the afternoon session.
Amarantus and BSI Proudly Announce BIO CEO & President Jim Greenwood as Panelist for 3rd Alzheimer's Focused #C4CT Concussion Awareness Summit at United Nations
GlobeNewswire - Tue Jul 22, 2:47PM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, and Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are proud to announce the Honorable Jim Greenwood, President & CEO of the Biotechnology Industry Organization (BIO), as a panelist for the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014, at the United Nations in New York City, NY.
Amarantus Discusses New Independent Peer-Reviewed Research Papers on MANF
GlobeNewswire - Fri Jul 18, 6:49AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has updated its MANF publications list with 8 previously undisclosed independent peer-reviewed research papers. The scientific articles include several Chinese publications as well as new publications that have been released since the beginning of 2014.
Amarantus BioScience Holdings, Inc. - "Understanding Data Presented at AAIC and Why Amarantus is Well Positioned Heading into #C4CT"
ACCESSWIRE - Thu Jul 17, 1:00PM CDT
New York, NY / July 17, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus and BSI Announce Continued Support of One Mind at the 3rd #C4CT Concussion Awareness Summit at the United Nations
GlobeNewswire - Thu Jul 17, 7:17AM CDT
Brewer Sports International (BSI), a multi-faceted global sports advisory firm, andAmarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, are pleased to announce their continued support of One Mind at the 3 Alzheimer's focused #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, powered by MDM Worldwide on Thursday, July 31, 2014 at the United Nations in New York City, NY.
Amarantus Announces Positive Clinical Performance and 7-Year Longitudinal Data Poster Presentations for LymPro Test (R) at AAIC 2014
GlobeNewswire - Tue Jul 15, 10:34AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive clinical performance data for Version 2 of the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. The LymPro Test clinical data package assessed was produced in 2008 at Provista Life Sciences. The 7-year longitudinal patient record clinical progression assessment data was conducted by Dr. Marwan Sabbagh at the Banner Sun Health Research institute who originally enrolled the 44 patients involved in the Provista clinical trial, and analyzed by Dr. Louis Kirby, the Company's Chief Medical Officer. LymPro differentially diagnosed Alzheimer's disease versus age-matched other dementias and cognitively intact controls in statistically significant manner. The poster presentations are available online at http://ir.stockpr.com/amarantus/scientific-publications.
Amarantus Announces Positive Analytical Performance Data Poster Presentation for LymPro Test (R) at AAIC 2014
GlobeNewswire - Mon Jul 14, 7:58AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive analytical performance data for the Company's proprietary cell cycle dysregulation diagnostic blood assay LymPro Test(R), currently under development for Alzheimer's disease diagnosis. The analytical data package, produced at the Company's contract laboratory BD Biosciences, provides the basis for reproducible clinical performance assessment of LymPro Test(R). The Company has performance univariate and multivariate analytical data analyses in an Alzheimer's population vs. a non-Alzheimer's population (cognitively intact, Parkinson's dementia and vascular dementia) to assess clinical performance. The Company will present pilot clinical performance data, and an up-to 6 year longitudinal assessment of the patients' clinical diagnosis change over time, in two complementary poster presentations on Tuesday July 15, 2014 at 11:45am local at AAIC 2014 in Copenhagen, Denmark (Poster position 117 and 118).
Amarantus BioScience Holdings "AAIC 2014: Understanding the Data Being Presented - LymPro Test(r) Version 2"
ACCESSWIRE - Wed Jul 09, 3:46PM CDT
New York, NY / ACCESSWIRE / July 9, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus' CEO to Host Twitter Chat on Thursday, July 10, 2014 at 4pm EDT
GlobeNewswire - Mon Jul 07, 3:25PM CDT
Amarantus BioScience Holdings, Inc. (OTCBB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will host and participate in a Twitter chat on Thursday, July 10, 2014 from 4-4:30pm EDT via his Twitter handle @G_Commish.
Amarantus Announces Three Data Presentations Related to the Company's LymPro Diagnostic Test at the Alzheimer's Association International Conference (AAIC)
GlobeNewswire - Mon Jul 07, 7:30AM CDT
Amarantus BioScience Holdings, (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that analytical performance, clinical performance and 6-year longitudinal data related to the Company's LymPro Test(R) will be presented at the Alzheimer's Association International Conference (AAIC), held at the Bella Center in Copenhagen, Denmark, July 12-17, 2014.
Amarantus Announces Positive Interim Toxicology Data for MANF in Retinitis Pigmentosa
GlobeNewswire - Wed Jul 02, 8:58AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced positive interim toxicology data for MANF in an ocular safety animal model, relevant to MANF development in Retinitis Pigmentosa. The data produced at a leading ophthalmology contract research laboratory using slit-lamp observations in rabbits demonstrated that an intravitreal injection with MANF was safe and well tolerated in the eye.
Active Trading Briefing For Innovative Advancers with Developing Operations - Company Enters Strategic Partnership With Renown Global Investment Advisory Firm
PR Newswire - Tue Jul 01, 7:45AM CDT
Operations and corporate developments lead to growth trends for advancing companies across various sectors: DirectView Holdings, Inc (OTC: DIRV), Amarantus Bioscience Holdings, Inc. (OTC: AMBS), The ADT Corporation (NYSE: ADT), Tyco International Ltd. (NYSE: TYC) and GoPro Inc. (NASDAQ: GPRO)
Amarantus Independently Confirms Published Chinese Positive MANF Tau Phosphorylation Data for Alzheimer's Disease
GlobeNewswire - Tue Jul 01, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced it has independently confirmed MANF's activity in mitigating tau hyperphosphorylation in pre-clinical models of Alzheimer's disease. The studies commissioned by Amarantus independently confirm data published in 2012 in the Chinese Pharmacological Bulletin entitled "MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells" in which the authors demonstrated that MANF had a pronounced effect in reducing Tau hyperphosphorylation, reducing cell death, and improving overall cellular health in in vitro models of Alzheimer's disease.
Amarantus BioScience Holdings, Inc. - "MANF Continues to Deliver Heading into 2H-14"
ACCESSWIRE - Mon Jun 30, 2:01PM CDT
New York, NY / June 30, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus and Brewer Sports Announce #C4CT Summit Morning Keynote Presentation by Congressman Chaka Fattah
GlobeNewswire - Wed Jun 25, 5:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International (BSI), today announced that Congressman Chaka Fattah will be delivering the morning keynote address at the #C4CT Concussion Awareness Summit focused on Traumatic Brain Injury-induced Alzheimer's disease at the United Nations on July 31, 2014. Congressman Fattah will address the Summit regarding policy initiatives currently underway to improve funding for Brain research.
Amarantus Bioscience Holdings, Inc. - "Marching Towards a Revolutionary Therapy for Blindness and Diabetes in Wolfram Syndrome"
ACCESSWIRE - Tue Jun 24, 10:01AM CDT
New York, NY / June 24, 2014 / Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) today published a guest blog post on The Chairman's Blog, written by Dr. Fumihiko Urano, a researcher at the Washington University School of Medicine. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus to Present at the 2014 BIO International Convention
GlobeNewswire - Mon Jun 23, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be presenting at the 2014 BIO International Convention on Thursday, June 26 at 11:45 AM PDT. The presentation will take place in the Mission Beach Room. Hosted by the Biotechnology Industry Organization (BIO), the conference will take place on June 23-26, 2014 at the San Diego Convention Center in San Diego, California.
Amarantus partners with Washington University School of MedicineJack to evaluate the efficacy of MANF to treat Wolfram disease
M2 - Mon Jun 23, 4:35AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) said on Friday that it plans to evaluate the efficacy of MANF to treat Wolfram-Syndrome-induced blindness in animals in a research partnership with the Washington University School of Medicine in St. Louis.
